Table 3 Study characteristics
variable | No.of patients (%) | OS | PFS |
|---|---|---|---|
P value | P value | ||
Age at primary Dx | |||
≥ 50 years | 40 (67) | 0.521 | 0.938 |
< 50 years | 20 (33) | ||
Tumor histology | |||
Adenocarcinoma | 4 (7) | 0.102 | 0.039 |
Squamous cell | 56 (93) | ||
Pre-treatment MRI-based maximal diameter (mm) | |||
>40 mm | 35(58) | 0.029 | 0.021 |
≤40 mm | 25(42) | ||
type of metastases | |||
LN only (lymphatic) | 50(83) | 0.017 | 0.153 |
Organ/organ + LN (hematogenous) | 10(17) | ||
Only one site lymph node metastases | |||
Supraclavicular lymph node | 32 (80) | 0.682 | 0.102 |
Inguinal lymph node | 8 (20) | ||
Number of lymph node metastatic sites (LN only) | |||
1 | 40 (80) | 0.146 | 0.478 |
2 | 10 (20) | ||
Number of metastatic sites at initial diagnosis | |||
1 | 43 (72) | 0.003 | 0.055 |
≥ 2 | 17 (28) | ||
Neoadjuvant chemotherapy | |||
yes | 29 (58) | 0.261 | 0.973 |
no | 21 (42) | ||
Chemotherapy circles | |||
≥ 4 | 26 (52) | 0.364 | 0.875 |
< 4 | 24 (48) | ||